Premium
Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells
Author(s) -
Hayashi Toshiaki,
Treon Steven P.,
Hideshima Teru,
Tai YuTzu,
Akiyama Masaharu,
Richardson Paul,
Chauhan Dharminder,
Grewal Iqbal S.,
Anderson Kenneth C.
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04322.x
Subject(s) - antibody dependent cell mediated cytotoxicity , monoclonal antibody , cytotoxicity , immunotherapy , antibody , multiple myeloma , recombinant dna , cd40 , monoclonal , medicine , cancer research , immunology , humanized antibody , cytotoxic t cell , biology , in vitro , immune system , biochemistry , gene
Summary. Multiple myeloma (MM) is currently incurable, and novel therapies are needed. In this study, we examined a novel recombinant humanized monoclonal antibody against CD40 (rhuCD40 mAb) and demonstrate for the first time that rhuCD40 mAb induces antibody‐dependent cell‐mediated cytotoxicity (ADCC) against CD40‐positive MM cells. Importantly, we show that rhuCD40 mAb induces autologous ADCC against primary patient MM cells, without triggering ADCC against normal B cells. This study, therefore, both demonstrates that rhuCD40 mAb triggers autologous ADCC against patient MM cells and provides the framework for the clinical evaluation of rhuCD40 mAb immunotherapy to improve patient outcome in MM.